Literature DB >> 29416929

A novel dysfunctional germline P53 mutation identified in a family with Li-Fraumeni syndrome.

Min Ji1, Lin Wang2, Yuguo Shao1, Wei Cao1, Ting Xu1, Shujie Chen1, Zhiwei Wang1, Qi He1, Kuo Yang2.   

Abstract

Li-Fraumeni Syndrome (LFS), which is a rare dominantly inherited cancer predisposition syndrome, is associated with germline P53 mutations. Mutations of the tumor suppressor protein P53 are associated with more than 50% of human cancers; however, almost 30% of P53 mutations occur rarely and this has raised questions about their significance. It therefore appeared of particular interest that we identified a novel mutation in a patient suffering from breast cancer and fulfilling the diagnostic criteria of LFS. In this study, a patient with remarkable family history developed breast cancer and was diagnosed with LFS. By performing next-generation sequencing on the patient and subsequent verification by Sanger sequencing among other family members, a new germ-line P53 replication error, a trinucleotide repeat mutation in the coding region, was identified in two generations of this Li-Fraumeni family.

Entities:  

Keywords:  Li-Fraumeni syndrome; P53 mutation; breast cancer

Year:  2018        PMID: 29416929      PMCID: PMC5794730     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  14 in total

1.  The C-terminus of p53: the more you learn the less you know.

Authors:  J Ahn; C Prives
Journal:  Nat Struct Biol       Date:  2001-09

2.  Regulation of the specific DNA binding function of p53.

Authors:  T R Hupp; D W Meek; C A Midgley; D P Lane
Journal:  Cell       Date:  1992-11-27       Impact factor: 41.582

Review 3.  The p53 pathway: positive and negative feedback loops.

Authors:  Sandra L Harris; Arnold J Levine
Journal:  Oncogene       Date:  2005-04-18       Impact factor: 9.867

4.  2009 version of the Chompret criteria for Li Fraumeni syndrome.

Authors:  Julie Tinat; Gaelle Bougeard; Stéphanie Baert-Desurmont; Stéphanie Vasseur; Cosette Martin; Emilie Bouvignies; Olivier Caron; Brigitte Bressac-de Paillerets; Pascaline Berthet; Catherine Dugast; Catherine Bonaïti-Pellié; Dominique Stoppa-Lyonnet; Thierry Frébourg
Journal:  J Clin Oncol       Date:  2009-08-03       Impact factor: 44.544

5.  Reciprocal interference between the sequence-specific core and nonspecific C-terminal DNA binding domains of p53: implications for regulation.

Authors:  M E Anderson; B Woelker; M Reed; P Wang; P Tegtmeyer
Journal:  Mol Cell Biol       Date:  1997-11       Impact factor: 4.272

Review 6.  Germline TP53 mutations and Li-Fraumeni syndrome.

Authors:  J M Varley
Journal:  Hum Mutat       Date:  2003-03       Impact factor: 4.878

7.  Allosteric activation of latent p53 tetramers.

Authors:  T R Hupp; D P Lane
Journal:  Curr Biol       Date:  1994-10-01       Impact factor: 10.834

8.  Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis.

Authors:  Shunsuke Kato; Shuang-Yin Han; Wen Liu; Kazunori Otsuka; Hiroyuki Shibata; Ryunosuke Kanamaru; Chikashi Ishioka
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-25       Impact factor: 11.205

Review 9.  p53 mutations in cancer.

Authors:  Patricia A J Muller; Karen H Vousden
Journal:  Nat Cell Biol       Date:  2013-01       Impact factor: 28.824

10.  Insight into a novel p53 single point mutation (G389E) by Molecular Dynamics Simulations.

Authors:  Davide Pirolli; Cristiana Carelli Alinovi; Ettore Capoluongo; Maria Antonia Satta; Paola Concolino; Bruno Giardina; Maria Cristina De Rosa
Journal:  Int J Mol Sci       Date:  2010-12-30       Impact factor: 5.923

View more
  2 in total

1.  Breast Cancer after Radiation Therapy in a Patient with Li-Fraumeni Syndrome: A Case Report.

Authors:  In Na Yoon; Eun Suk Cha; Jeoung Hyun Kim; Jee Eun Lee; Jin Chung
Journal:  Taehan Yongsang Uihakhoe Chi       Date:  2021-10-18

2.  A Functional Precision Medicine Pipeline Combines Comparative Transcriptomics and Tumor Organoid Modeling to Identify Bespoke Treatment Strategies for Glioblastoma.

Authors:  Megan R Reed; A Geoffrey Lyle; Annick De Loose; Leena Maddukuri; Katrina Learned; Holly C Beale; Ellen T Kephart; Allison Cheney; Anouk van den Bout; Madison P Lee; Kelsey N Hundley; Ashley M Smith; Teresa M DesRochers; Cecile Rose T Vibat; Murat Gokden; Sofie Salama; Christopher P Wardell; Robert L Eoff; Olena M Vaske; Analiz Rodriguez
Journal:  Cells       Date:  2021-12-02       Impact factor: 7.666

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.